Last updated: 2026-09-09 05:06:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neurogene, Inc. (NGNE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $38.28, with a market capitalisation of $772.44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.93 to $43.66. This page covers its latest market performance, valuation, price trends and company information.
$772.44M | |
$37.79 | |
$74.49 | |
$6.88 | |
$38.60 | |
216.98K | |
241.70K | |
-- | |
$43.66 | |
$15.93 | |
-- | |
-- |
Neurogene, Inc. (NGNE) last closed at $38.60 as of 2026-09-08 21:40:00, unchanged from the previous close of $38.60.
During the latest regular trading session, NGNE traded between $6.88 and $74.49, with a volume of 216.98K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Neurogene, Inc. (NGNE) moved from $37.86 to $38.28, representing a gain of 1.11% ($0.42).
The stock traded between $35.26 and $39.81 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 178.77 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.6%
NGNE is currently trading at $38.28, placing it 80.6% of the way from its 52-week low of $15.93 to its 52-week high of $43.66. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 131 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neurogene, Inc. (NGNE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.